PYPB Stock Chart & Stats
€0.08
€0.00(0.00%)
At close: 4:00 PM EDT
€0.08
€0.00(0.00%)
Day’s Range― - ―
52-Week Range€0.07 - €0.15
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€26.14M
Enterprise Value€6.18M
Total Cash (Recent Filing)€1.68M
Total Debt (Recent Filing)€559.00K
Price to Earnings (P/E)―
Beta-0.06
Next Earnings
Dec 08, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.02
Shares Outstanding218,974,290
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.13
Price to Book (P/B)1.01
Price to Sales (P/S)1.81
P/FCF Ratio-12.69
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.02
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Order-book VisibilityThe record order book and 95% coverage of full-year guidance provide unusually strong near-term revenue visibility for a project-based services business. This supports resource planning, reduces dependence on winning immediate contracts, and indicates that customer demand is converting into contracted work.
Revenue And Margin ImprovementStrong H1 growth combined with a higher gross margin suggests improving operating economics as IXICO handles more advanced studies and automated analysis. If this mix persists, greater scale can support better contribution from each project and strengthen the path toward future profitability.
Strategic Medidata PartnershipIntegration with Medidata can broaden IXICO's distribution and embed its analytics within an established clinical-development workflow. Access to a platform serving a large share of FDA-approved programs may improve scalability, validate the productization strategy, and support repeat commercial opportunities.
Bears Say
Persistent Losses And Weak Cash GenerationNegative operating cash flow and continuing EBITDA losses show that the current business model has not yet reached self-funded profitability. This can require further financing or strict investment control, while ongoing losses limit the company's ability to compound growth from internally generated cash.
Long Path To Recurring TechBio RevenueThe TechBio strategy may create recurring revenue, but its commercial and regulatory timelines defer meaningful benefits for several periods. Continued investment before monetization could weigh on results, leaving the company dependent on services revenue and external funding while the platform develops.
Exposure To Trial Descopes And CancellationsBecause revenue is tied to clinical-trial activity, descopes or cancellations can reduce planned scan volumes, analysis work, and milestone receipts. This creates structural variability in revenue conversion and makes future performance dependent not only on contract wins but also on the continued progress of customers' trials.
IXICO plc News
PYPB FAQ
What was IXICO PLC’s price range in the past 12 months?
IXICO PLC lowest stock price was €0.07 and its highest was €0.15 in the past 12 months.
What is IXICO PLC’s market cap?
IXICO PLC’s market cap is €26.14M.
When is IXICO PLC’s upcoming earnings report date?
IXICO PLC’s upcoming earnings report date is Dec 08, 2026 which is in 44 days.
How were IXICO PLC’s earnings last quarter?
IXICO PLC released its earnings results on May 19, 2026. The company reported -€0.014 earnings per share for the quarter.
Is IXICO PLC overvalued?
According to Wall Street analysts IXICO PLC’s price is currently Overvalued.
Does IXICO PLC pay dividends?
IXICO PLC does not currently pay dividends.
What is IXICO PLC’s EPS estimate?
IXICO PLC’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does IXICO PLC have?
IXICO PLC has 218,974,290 shares outstanding.
What happened to IXICO PLC’s price movement after its last earnings report?
IXICO PLC reported an EPS of -€0.014 in its last earnings report. Following the earnings report the stock price went up 1.515%.
Which hedge fund is a major shareholder of IXICO PLC?
Currently, no hedge funds are holding shares in DE:PYPB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
IXICO PLC
IXICO plc, a London-based company established in 1995, specializes in providing data analytics services to the global biopharmaceutical industry. Operating across the UK, Europe (including Switzerland, Netherlands, Ireland), the United States, and internationally, IXICO supports clinical trials by managing the entire lifecycle of study-generated data, from acquisition and processing to in-depth analysis and comprehensive reporting. They leverage proprietary technology platforms like Assessa, a secure digital tool that aids clinical decision-making for patient selection and post-market monitoring, and TrialTracker, which streamlines intricate imaging workflows, handling everything from initial image uploads and quality control to expert analysis, interpretation, and final data delivery within clinical research. IXICO's expertise is concentrated on neurological disorders, including Alzheimer's, Parkinson's, Huntington's, Multiple Sclerosis and other demyelinating conditions, Progressive Supranuclear Palsy, and various rare neurological diseases. Their services encompass not only the collection, optimization, and analytics for rare neurological disorders but also drug development analytics, specialized imaging operations, post-market surveillance support, and expert consultancy. The company delivers comprehensive, end-to-end services for clinical trials, covering initial trial design and consultation, meticulous project management, imaging site setup and management, robust data management, expert image reading and analysis, and guidance on regulatory pathways.
Technical Analysis
Avacta Group plc
―
Oxford BioDynamics
―
Physiomics
―
Open Orphan Plc
―
Aptamer Group Plc
―









